Sökning: "ibrutinib"
Visar resultat 1 - 5 av 15 avhandlingar innehållade ordet ibrutinib.
1. Mantle cell lymphoma strategies in primary treatment
Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER
2. Immune cells in chronic lymphocytic leukemia and Hodgkin lymphoma in relation to tumor burden and treatment
Sammanfattning : B-cell malignancies are a heterogeneous group of cancers that originate from lymphoidlineage cells that are responsible for humoral immunity. When B-cell development goes wrong, chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), among other malignancies, may arise. Recent advances in the treatment of these diseases, e.g. LÄS MER
3. Targeted therapy in chronic lymphocytic leukemia
Sammanfattning : Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 aberration and with refractoriness to chemoimmunotherapy had a dismal prognosis. LÄS MER
4. Estrogen regulation of non-Hodgkin lymphomas and its underlying mechanisms
Sammanfattning : Most non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), show a higher male to female incidence ratio. The reason for this is not clear, but epidemiological and experimental studies have suggested a role for estrogens in NHL acting via estrogen receptor β (ERβ). LÄS MER
5. Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy
Sammanfattning : BTK inhibitors have induced high response rates in the treatment of leukemias and lymphomas. Ibrutinib is the first-in-class US Food and Drug Administration (FDA)-approved BTK covalent inhibitor to treat chronic lymphocytic leukemia (CLL). However, a sub-group of patients develops resistance to ibrutinib therapy. LÄS MER